

Table SI. Clinical findings and evaluation of 7-AABs alone or in combination with non-specific tumor markers for patients with early-stage malignant lung nodules.

Group	Clinical finding	Stage 0	Stage I	P-value	χ^2 -value
7-AABs	Positive	32	35	1.4	0.232
	Negative	34	55		
7-AABs + HSP90a	Positive	59	77	0.5	0.479
	Negative	7	13		
7-AABs + CEA	Positive	33	39	0.7	0.409
	Negative	33	51		
7-AABs + CYFRA21-1	Positive	37	40	2.1	0.152
	Negative	29	50		
7-AABs + CA199	Positive	32	37	0.8	0.360
	Negative	34	53		
7-AABs + CA125	Positive	34	40	0.8	0.382
	Negative	32	50		

7-AABs, seven lung cancer-related autoantibodies; CEA, carcinoembryonic antigen; CYFRA21-1, cytokeratin fragment antigen 21-1; CA199, carbohydrate antigen 199; CA125, carbohydrate antigen 125; HSP90a, heat shock protein 90a. Data were analyzed by using the chi-square test.